RBT and the Complex Case Clinic have launched a study of personalized immunotherapy in dogs with B-cell lymphoma. The study is based on immunotherapy. It involves activating an adaptive immune response against the individual antigenic profile of the tumor.

RBT and the Almazov Center have signed an agreement to conduct joint research on a solution for storing human organs in order to register it as a medical device and scale up production. Solution was developed by the Almazov Center. Main goal of the agreement is to further produce and commercialize the solution by RBT.

RBT is launching the production of a set for creating personalized vaccines for the treatment of cancer in small pets. RBT vaccines activate the pet's immune system to fight the tumor. Currently, there are only two solutions in the line: a set for creating a personalized multi-antigen vaccine against lymphomas in cats and dogs, and a set with the Betusfera a...

Artgen will buy back RBT shares from investors who invested at least ₽1 million during the 2023 Rounds platform placement and retained ownership of the shares since their purchase. Buyback will be conducted at the investment price. Holders of the shares can exercise their right between April 20 and May 20, 2026.